NGL Fine-Chem (Animal Health + Human Health + Vet Formulations)

Notes from AR iro NGL Finechem for FY 21-22 –

1. A prominent animal healthcare company in India with a global footprint. A leading manufacturer of animal APIs, advanced intermediates and finished dosage forms. Has 3 state of the art manufacturing facilities in Maharashtra – two at Tarapur and one at Navi Mumbai.
2. Current product portfolio of 21 animal APIs, 02 human APIs, 04 intermediates and 10 formulations. Revenue breakdown –
   Veterinary APIs – 82 pc
   Human APIs – 7 pc
   Intermediates – 9 pc
   Formulations – 3 pc

Geography wise revenue breakdown –
India – 24 pc
Europe – 28 pc
US – 3 pc
Asia Pacific – 30 pc
RoW – 15 pc

Company has 50 pc plus mkt share in top 3 of its products.

3. Key performance highlights –

Veterinary APIs grew 26 YoY in FY 21-22
Revenues increased to 318 cr from 258 cr
EBITDA at 69 cr vs 77 cr
PAT at 53 cr vs 55 cr
EBITDA margins at 21 pc vs 30 pc

Aim to launch 3-4 products per year. Currently have 5 molecules in pipeline, each with multi step synthesis. These products are likely to be margin accretive. Their newly launched poultry molecule has shown wide acceptance and is clocking in good sales. Company completed expansion at Macrotech’s plant ( subsidiary ) in the FY 21-22. Also added capacities with brown filed expansion at Tarapur.

4. Animal healthcare mkt likely to grow at 5pc CAGR upto 2027. Bulk of company’s products cater to the cattle market and the company expects the trend to continue in future as well. Company’s 4 yr CAGR for revenue, EBITDA and PAT stands at 27 pc, 34 pc and 41 pc !!! Company is likely to out source 15 pc of its manufacturing to cater to increasing demand. Also, 50 pc capacity expansion ( Greenfield ) at Tarapur is lined up. Total outlay for this capex is 140 cr. Likely to be completed by next FY.

Disc : invested, biased.